MYDECINE INNOVAT.GRP
Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pha… Read more
MYDECINE INNOVAT.GRP (0NF0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MYDECINE INNOVAT.GRP (0NF0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MYDECINE INNOVAT.GRP - Net Assets Trend (None–None)
This chart illustrates how MYDECINE INNOVAT.GRP's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MYDECINE INNOVAT.GRP (None–None)
The table below shows the annual net assets of MYDECINE INNOVAT.GRP from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MYDECINE INNOVAT.GRP's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MYDECINE INNOVAT.GRP Competitors by Market Cap
The table below lists competitors of MYDECINE INNOVAT.GRP ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medite Cancer Diagnostics Inc
PINK:MDIT
|
$1.73K |
|
ZHUGUANG HOLDINGS
BE:NA7
|
$1.73K |
|
PT Timah Tbk
MU:TIH1
|
$1.73K |
|
QUESTERRE ENERGY-A
MU:QE1
|
$1.73K |
|
Thanh Nam Group JSC
VN:TNI
|
$1.73K |
|
Alchemy Investments Acquisition Corp 1 Warrants
NASDAQ:ALCYW
|
$1.73K |
|
SPC Power Corp
PSE:SPC
|
$1.73K |
|
ECOBANK TRANSNATIONAL INCORPORATION
GSE:ETI
|
$1.72K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MYDECINE INNOVAT.GRP's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MYDECINE INNOVAT.GRP's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MYDECINE INNOVAT.GRP utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MYDECINE INNOVAT.GRP's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MYDECINE INNOVAT.GRP (0NF0) | €- | N/A | N/A | $1.73K |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |